Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Opzelura® (ruxolitinib) – New indication
July 18, 2022 - Incyte announced the FDA approval of Opzelura (ruxolitinib) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
